Skip to main content
Equibles
LTRN logo

LTRN · Lantern Pharma Inc. · Metrics

Track LTRN — free

Use LTRN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LTRN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.68 +0.04 (+6.20%) Q4 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding. While the Company plans to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend the Company's operating runway, no assurance can be given that sufficient funding will be available when needed to allow the Company to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$8.18M
Shares
12.78M
Volume · Oct 28 52.16K Avg daily vol (3M) 217.39K

LTRN metrics

66 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.64
Market cap
$8.18M

Price action

20 metrics
Price change (1W)
-2.5%
Price change (30D)
-41.3%
Price change (3M)
-75.4%
Price change (6M)
-71.4%
Price change (YTD)
-78.9%
Price change (1Y)
-84.2%
Trailing year
Price change (5Y)
-93.7%
52-week high
$4.17
52-week low
$0.62
Change from 52-week high
-84.7%
Change from 52-week low
+2.6%
Annualized volatility
99.9%
Annualized volatility (3M)
79.1%
Beta
2.8
RSI (14D)
21.9
Price vs SMA 50
-54.2%
Price vs SMA 200
-74.4%
Avg volume (3M)
217,394
Relative volume
0.3
Average dollar volume
$295,970

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
12.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
31.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-233.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
31.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$15.47M
Net income (TTM)
−$18.65M
Trailing 12 months
Diluted EPS (TTM)
$-1.62
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.36
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.61
Operating cash flow per diluted share (TTM)
$-1.24
Free cash flow per diluted share (TTM)
$-1.44
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.77
Stock compensation per diluted share (TTM)
$0.06
Book value per share
$0.58

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-216.8%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7.36M
Latest balance sheet
Cash & equivalents
$6.66M
Total assets
$8.60M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.08M
Capital expenditures (TTM)
$1,715
R&D (TTM)
$8.70M
SG&A (TTM)
—
Stock compensation (TTM)
$890,799
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
39
13F filer change QoQ
+6
Institutional ownership
22.6%
Conviction holders (share of 13F filers)
5.1%
Crowding (high-turnover and private-fund holders)
14.0%
Private-fund adviser ownership
13.5%
Active holders' share change QoQ
+48.3%
Holder tenure
8.3
Price vs estimated holder cost
-1.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.0%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
31 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1763950 CUSIP 51654W101 13F (30d) 4 filings 4 filers Visit website Investor relations